Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHA:600488)
4.270
+0.070 (1.67%)
Feb 4, 2026, 3:00 PM CST
SHA:600488 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,849 | 3,190 | 3,755 | 3,666 | 3,735 | 3,106 |
Other Revenue | 25.76 | 25.76 | 27.48 | 22.56 | 13.35 | 10.65 |
| 2,875 | 3,215 | 3,783 | 3,689 | 3,749 | 3,117 | |
Revenue Growth (YoY) | -18.27% | -15.00% | 2.54% | -1.59% | 20.27% | -6.31% |
Cost of Revenue | 1,689 | 1,796 | 2,079 | 1,933 | 2,016 | 1,734 |
Gross Profit | 1,186 | 1,419 | 1,704 | 1,756 | 1,732 | 1,383 |
Selling, General & Admin | 819.47 | 930.58 | 1,337 | 1,394 | 1,385 | 1,054 |
Research & Development | 154.41 | 199.87 | 157.67 | 139.45 | 128.87 | 131.83 |
Other Operating Expenses | 14.3 | 18.53 | 29.44 | 40.9 | 40.15 | 18.77 |
Operating Expenses | 988.67 | 1,149 | 1,524 | 1,575 | 1,554 | 1,205 |
Operating Income | 197.11 | 269.96 | 179.93 | 181.37 | 178.2 | 178.02 |
Interest Expense | -21.24 | -28.82 | -36.69 | -48.16 | -45.91 | -40.19 |
Interest & Investment Income | 11.09 | 8.12 | 8.57 | 4.42 | 7.08 | 2.29 |
Currency Exchange Gain (Loss) | 13.67 | 13.67 | 11.83 | 16.28 | 1.37 | -3.29 |
Other Non Operating Income (Expenses) | -80.72 | -1.18 | -0.92 | -1.86 | -2.54 | -23.32 |
EBT Excluding Unusual Items | 119.92 | 261.76 | 162.72 | 152.05 | 138.21 | 113.51 |
Gain (Loss) on Sale of Investments | -8.66 | -9.09 | -1.13 | -22.44 | - | -1.22 |
Gain (Loss) on Sale of Assets | 0.72 | -0.1 | 0.65 | -0.99 | -0.06 | -0.21 |
Asset Writedown | -21.18 | -34.56 | -8.18 | -73.02 | -4.37 | - |
Other Unusual Items | 8.5 | 8.5 | 14.18 | -43.1 | 15.29 | 0.3 |
Pretax Income | 99.3 | 226.51 | 168.24 | 12.52 | 149.07 | 112.38 |
Income Tax Expense | 17.66 | 18.3 | 5.57 | -5.92 | 40.4 | 31.8 |
Earnings From Continuing Operations | 81.64 | 208.21 | 162.67 | 18.44 | 108.67 | 80.58 |
Minority Interest in Earnings | -65.35 | -74.76 | -45.62 | 16.97 | -60 | -46.6 |
Net Income | 16.3 | 133.45 | 117.05 | 35.41 | 48.67 | 33.98 |
Net Income to Common | 16.3 | 133.45 | 117.05 | 35.41 | 48.67 | 33.98 |
Net Income Growth | -89.28% | 14.01% | 230.60% | -27.25% | 43.23% | -79.00% |
Shares Outstanding (Basic) | 1,090 | 1,094 | 1,094 | 1,106 | 1,082 | 1,096 |
Shares Outstanding (Diluted) | 1,090 | 1,094 | 1,094 | 1,106 | 1,082 | 1,096 |
Shares Change (YoY) | -0.37% | -0.01% | -1.13% | 2.31% | -1.33% | 0.28% |
EPS (Basic) | 0.01 | 0.12 | 0.11 | 0.03 | 0.04 | 0.03 |
EPS (Diluted) | 0.01 | 0.12 | 0.11 | 0.03 | 0.04 | 0.03 |
EPS Growth | -89.24% | 14.02% | 234.38% | -28.89% | 45.16% | -79.05% |
Free Cash Flow | 79.18 | 491.63 | 649.86 | 451.33 | -53.95 | -111.63 |
Free Cash Flow Per Share | 0.07 | 0.45 | 0.59 | 0.41 | -0.05 | -0.10 |
Dividend Per Share | 0.098 | 0.098 | 0.087 | 0.010 | 0.014 | 0.010 |
Dividend Growth | 12.64% | 12.64% | 770.00% | -28.57% | 40.00% | -75.00% |
Gross Margin | 41.25% | 44.13% | 45.04% | 47.61% | 46.21% | 44.36% |
Operating Margin | 6.86% | 8.40% | 4.76% | 4.92% | 4.75% | 5.71% |
Profit Margin | 0.57% | 4.15% | 3.09% | 0.96% | 1.30% | 1.09% |
Free Cash Flow Margin | 2.76% | 15.29% | 17.18% | 12.23% | -1.44% | -3.58% |
EBITDA | 499.92 | 559.08 | 450.78 | 438.18 | 383.2 | 361.77 |
EBITDA Margin | 17.39% | 17.39% | 11.92% | 11.88% | 10.22% | 11.61% |
D&A For EBITDA | 302.82 | 289.12 | 270.85 | 256.81 | 205 | 183.75 |
EBIT | 197.11 | 269.96 | 179.93 | 181.37 | 178.2 | 178.02 |
EBIT Margin | 6.86% | 8.40% | 4.76% | 4.92% | 4.75% | 5.71% |
Effective Tax Rate | 17.79% | 8.08% | 3.31% | - | 27.10% | 28.30% |
Revenue as Reported | 2,875 | 3,215 | 3,783 | 3,689 | 3,749 | 3,117 |
Advertising Expenses | - | 249.58 | 543.79 | 645.43 | 650.67 | 416.15 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.